Sheryl A. Zelenitsky

TL;DR: Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus β-lactamase-producing Gram-negative bacilli that are not inhibited by ceftAZidime alone.

TL;DR: Time-kill experiments and animal infection models have demonstrated that the pharmacokinetic–pharmacodynamic index that is best correlated with ceftolozane’s in vivo efficacy is the percentage of time in which free plasma drug concentrations exceed the minimum inhibitory concentration of a given pathogen, as expected of β-lactams.

TL;DR: Clinical trials involving patients with complicated skin and skin structure infections (cSSSIs) have demonstrated that all three agents are as efficacious as comparators, and the most common adverse effects reported with dalbavancin use included nausea, diarrhoea and constipation.

TL;DR: The addition of relebactam significantly improves the activity of imipenem against most species of Enterobacteriaceae depending on the presence or absence of β-lactamase enzymes, and the pharmacokinetics of vaborbact am are described by a two-compartment, linear model and do not appear to be altered by the co-administration of imIPenem and meropenem, respectively.

TL;DR: Cefiderocol is unique in that it enters the bacterial periplasmic space as a result of its siderophore-like property and has enhanced stability to β-lactamases, and its total activity against meropenem–non-susceptible and Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriales is comparable or superior to ceftazidime-avibactam.